New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a continge ...

NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a continge ...

SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Commercial Viability Risks: Levi & KorsinskyMar 24, 2026 4:00 PM Eastern Daylight TimeSLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Commercial Viability Risks: Levi & KorsinskyShareTime-Sensitive: Allegations Focus on Undisclosed ...

Robbins LLP Urges SLNO Stockholders Who Lost Money Investing in Soleno Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action Accessibility StatementSkip Navigation SAN DIEGO, March 23, 2026 /PRNewswire/ -- Robbins LLPreminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing ...

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a continge ...

Did you buy SLNO common stock between March 26, 2025, and November 4, 2025? Affected Soleno Therapeutics, Inc. Investor Summary Who: Soleno Therapeutics, Inc. (NASDAQ: SLNO)What: Securities fraud class action lawsuit filedClass Period: March 26, 2025, through November 4, 2025Deadline to Seek Lead Plaintiff Status: May 5, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s Phase 3 clinical trial program for diazoxide choline extended-release tablets (“DCCR”).Investor ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Soleno Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3] Group 1: Class Action Details - Investors who bought Soleno common stock between March 26, 2025, and November 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 5, 2026 [3] Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4] - The firm has achieved notable settlements, including over $438 million in 2019, and has been consistently ranked among the top firms in securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that Soleno made false or misleading statements regarding the safety of its Phase 3 clinical trial program for diazoxide choline extended-release tablets (DCCR), particularly concerning safety risks related to fluid retention [5] - It is claimed that the administration of DCCR posed greater safety risks than disclosed, affecting its commercial viability and leading to potential adverse events post-launch [5]

Core Viewpoint - The Soleno Therapeutics, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims centered around undisclosed safety concerns related to its only commercial product, DCCR, for treating hyperphagia in Prader-Willi syndrome patients [1][3]. Company Overview - Soleno Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for rare diseases, with its primary product being diazoxide choline extended-release tablets (DCCR) [2]. Allegations of the Lawsuit - The lawsuit alleges that Soleno and its executives failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [3]. - It is claimed that the administration of DCCR posed materially greater safety risks than disclosed, leading to lower commercial viability and undisclosed risks of adverse events post-launch [3]. - The lawsuit cites a critical report by Scorpion Capital LLC that negatively impacted Soleno's stock price, leading to a nearly 12% decline over two trading days [4]. Impact on Stock Price - Following the report by Scorpion Capital, Soleno's stock price dropped approximately 19% after a patient death was reported related to DCCR [5]. - On November 4, 2025, Soleno reported a disruption in DCCR's launch trajectory, resulting in a further 27% decline in stock price due to concerns raised within the Prader-Willi syndrome community [6]. Legal Process - Investors who purchased Soleno common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to act on behalf of all class members [7]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [8]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm representing investors in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [9].

Core Viewpoint - The lawsuit against Soleno Therapeutics, Inc. alleges that the company misrepresented safety concerns related to its product DCCR, leading to significant financial losses for investors during the class period from March 26, 2025, to November 4, 2025 [4]. Group 1: Lawsuit Details - The lawsuit claims that Soleno downplayed and concealed safety concerns regarding DCCR, particularly issues related to excess fluid retention in clinical trial participants [4]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, affecting its commercial viability and leading to undisclosed risks such as patient discontinuation rates and prescriber reluctance [4]. - Investors who suffered losses have until May 5, 2026, to request lead plaintiff appointment, which allows them to oversee the litigation on behalf of the class [2]. Group 2: Impact on Stock Price - Following a report by Scorpion Capital on August 15, 2025, which labeled DCCR as overpriced and potentially unsafe, Soleno's share price fell by $5.73, or approximately 7.41%, from $77.36 to $71.64 [5]. - On September 10, 2025, after a patient death was reported related to DCCR, the stock price dropped by $10.20, or about 14.53%, from $70.21 to $60.01 [6]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed an 8% discontinuation rate for DCCR due to adverse effects, resulting in a significant share price decline of $16.98, or approximately 26.59%, from $63.85 to $46.87 [7].